SAN FRANCISCO—“Interstitial lung disease is the last bastion of great medicine,” according to Paul Noble, MD, chair, Department of Medicine, director, Women’s Guild Lung Institute, Vera and Paul Guerin Distinguished Chair in Pulmonary Medicine, Cedars-Sinai Medical Center, Los Angeles. Making it great medicine, he said, are the many things still unknown about this disease.
Explore this issueJanuary 2016
Also by this Author
In a presentation titled, The Changing Landscape in Fibrosing Lung Diseases, held at the 2015 ACR/ARHP Annual Meeting, Dr. Noble traversed the challenging terrain of accurate diagnosis of interstitial lung disease (ILD) given the multiple connective tissue disorders that may underlie ILD, such as scleroderma and rheumatoid arthritis (RA), as well as the many patients who fall into the gray area of undifferentiated connective tissue disease in which the disease has not yet fully revealed itself.
Dr. Noble focused his talk on the large gray area of undifferentiated connective tissue disease in which most patients with ILD fall and, in particular, on those patients with idiopathic interstitial pneumonia with autoimmune features.